Supplementary Figure S3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study | Synapse
August 20, 2025Open Access
Supplementary Figure S3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Puntos clave
Tumor fraction change is predictive of outcomes in patients undergoing immune checkpoint inhibitors.
Baseline detection of tumor fraction appears to have prognostic significance, guiding future interventions.
Assessment of tumor fraction change in a real-world setting can offer insights into clinical benefits of treatment.
Findings may enable better patient selection for immune checkpoint inhibitor therapy in oncological practice.
Resumen
Baseline TF detection is prognostic but TF change is predictive of outcome